Lead: Soban Sadiq, Yuki Ka Ling Shum
The Cardiovascular Pharmacology Unit is led by qualified pharmacists or pharmacologists. We have studied cardiovascular risk in a variety of conditions and the comparative drug actions on adverse cardiovascular outcomes:
Publications
1. Mui, J.V., Zhou, J., Lee, S., Leung, K.S.K., Lee, T.T.L., Chou, O.H.I., Tsang, S.L., Wai, A.K.C., Liu, T., Wong, W.T., Chang, C., Tse, G.*, Zhang, Q.* (2021) Sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors for new onset dementia: a propensity score-matched population-based study with competing risk analysis. Frontiers in Cardiovascular Medicine. https://doi.org/10.3389/fcvm.2021.747620. Impact factor: 6.1.
2. Lee, S., Zhou, J., Leung, K.S.K., Wai, A.K.C., Jeevaratnam, K., King, E., Liu, T., Wong, W.T., Chang, C., Wong, I.C.K., Cheung, B.M., Tse, G.*, Zhang, Q.* (2021) Comparison of sodium glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risk of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-021-07245-4. 5-year impact factor: 4.1.
3. Zhou, J., Lee, S., Leung, K.S.K., Wai, A.K.C., Liu, T., Liu, Y., Chang, D., Wong, W.T., Wong, I.C.K., Cheung, B.M., Zhang, Q.*, Tse, G.* (2021) Heart failure and myocardial infarction in sodium-glucose cotransporter 2 versus dipeptidyl peptidase-4 inhibitor users. ESC Heart Failure. https://doi.org/10.1002/ehf2.13582. Impact factor: 4.4.
4. Sfairopoulos, D., Zhang, N., Wang, Y., Chen, Z., Letsas, K.P., Tse, G., Li, G., Lip, G.Y.H., Liu, T., Korantzopoulos, P. (2021) Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials. Europace. https://doi.org/10.1093/europace/euab177. 5-year impact factor: 5.3.
5. Zhang, N, Tse, G., Liu, T. (2021) Neutrophil-lymphocyte ratio in the immune checkpoint inhibitors-related atherosclerosis. European Heart Journal. PMID: 33748846. https://doi.org/10.1093/eurheartj/ehab158. 5-year impact factor: 30.0.
6. Guo, S., Tse, G., Liu, T. (2020) Cardioprotective strategies to prevent trastuzumab-induced cardiotoxicity. Lancet. 15;395(10223):491-492. PMID: 32061289. https://doi.org/10.1016/S0140- 6736(19)32549-8. Impact factor: 59.
7. Ju, C., Lai, R.W.C., Li, K.H.C., Hung, J.K.F., Lai, J.C.N., Ho, J., Liu, Y., Tsoi, M.F., Liu, T., Cheung, B.M.Y., Wong, I.C.K., Tam, L.S., Tse, G.* (2019) Comparative cardiovascular risk in users versus non- users of xanthine oxidase inhibitors and febuxostat versus allopurinol users. Rheumatology. PMID: 31873735. https://doi.org/10.1093/rheumatology/kez576. Impact factor: 5.7.
8. Roever, L., Tse, G., Versaci, F., Biondi-Zoccai, G. (2019) Admission glucagon-like peptide-1 levels in acute myocardial infarction: is this really a new biomarker of cardiovascular risk? European Heart Journal. PMID: 31834367. https://doi.org/10.1093/eurheartj/ehz868. Impact factor: 25.
9. Tse, G., Gong, M., Li, G., Wong, S.H., Wu, W.K.K., Wong, W.T., Roever, L., Lee, A.P.W., Lip, G.Y.H., Wong, M.C.S., Liu, T. (2018) Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. British Journal of Clinical Pharmacology. 84(9):1868-1882. PMID: 29704269. https://doi.org/10.1111/bcp.13621. 5-year impact factor: 4.2.